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We read with interest the article by Yu¨ksel et al.1 on the
immunogenicity of the Haemophilus inﬂuenzae type b–tetanus
conjugate vaccine when administered separately or in combined
form in Turkey, and congratulate them on their study.
According to the latest World Health Organization recommen-
dations, vaccination against Haemophilus inﬂuenzae type b (Hib)
should be included in the routine infant immunization schedule
after due consideration by the national authorities. Hib is the most
common cause of meningitis and pneumonitis in children aged less
than 5 years in India. Hib meningitis has a very high mortality, and
many survivors suffer from long-term sequelae. The Hib vaccine is
a highly efﬁcacious and safe vaccine, and a booster dose at 15–18
months of age is necessary to boost the antibodies further for a
long-lasting serum level. Hib combination vaccines, including
those with inactivated polio vaccine (IPV), diphtheria–whole cell
pertussis–tetanus (DPwT) or diphtheria–acellular pertussis–teta-
nus (DPaT), and hepatitis B virus are safe and effective and should
be encouraged to improve compliance. The use of the Hib vaccine is
recommended in India for those who can afford the vaccine.
Providing the Hib vaccination along with the recommended
DPT and oral polio vaccine (OPV) would help to increase
compliance with vaccination. It would also ensure that the child
receives the vaccines at an age at which they are most likely to
contract an infection. The above study shows that the long-term
protection is better with individual vaccines. However the fact
remains that the immediate immunogenicity is not affected by
whether the vaccinations are separate or combined.2 In addition,
with combined vaccinations there would be a lesser chance of side
effects and a lesser number of needle pricks for the child. The cost
of combined vaccines may be high, but the consolidated advantage
that a combined vaccine gives far outweighs its price tag. An1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.05.1034effective primary vaccination schedule for the Hib vaccine matches
that recommended for the DTP vaccine, which has been available
for many years. In addition, the OPV and hepatitis B vaccine can be
added to the same schedule.
The introduction of the Hib vaccine by the government might
result in increased health expenditure, but this could easily be
balanced by the mortality and morbidity prevented. In places
where the combined vaccine is ﬁnancially viable, it could be used
effectively to decrease the burden of this disease.3
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